Physician profile
Michael E Foster
NPI 1447397427
$707.02
in general payments reported to CMS, 2019-2025
12 companies · $506 in 2025
The $506 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $89.38 · 2024: $112 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $707.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $177.60 | 2024-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Acera Surgical, INC. | $93.41 | 2023-2025 | Restrata Wound Matrix |
| Kerecis Limited | $77.69 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Smith+Nephew, INC. | $60.59 | 2025 | Collagenase Santyl, Pico 7 |
| Integra Lifesciences Corporation | $60.23 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Urgo Medical North America, LLC | $51.14 | 2024-2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Vertex Pharmaceuticals Incorporated | $47.45 | 2025 | |
| Solventum Corporation | $42.03 | 2024-2025 | V.A.C. Veraflo, V.A.C.Ulta, Prevena |
| Biotissue Holdings INC. | $41.54 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.25 | 2025 | Gattex |
| Hologic Sales and Service, LLC | $20.00 | 2024 | Trident Specimen Radiography System, Trunode |
| Sanara Medtech INC. | $15.09 | 2025 | Celleraterx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.